Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Variantyx logo — Variantyx is a technology-driven precision medicine company...

Variantyx

Variantyx is a technology-driven precision medicine company providing state-of-the-art genomic testing.

Founded 2014 United States Framingham, United States 221 employees Series D Total: $136.50M Biotechnology, Health Care +1

General Information

Company Name Variantyx
Founded Year 2014
Location United States Framingham, United States
Employees 221
Industries Biotechnology, Health Care, Life Sciences
Funding Stage Series D
Business Model B2B, B2C, B2D
Revenue Model Service Fee, Transaction Fee, Usage Based
Social

BounceWatch is an independent company data service, not affiliated with Variantyx. To contact Variantyx, visit variantyx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Variantyx compare?

A PDF of Variantyx and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Variantyx soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Variantyx

Variantyx, founded in 2014, is a pioneering force in precision medicine, specializing in diagnostic solutions for rare genetic disorders and reproductive genetics. Operating within the realms of Biotechnology, Health Care, and Life Sciences, this United States-based company harnesses advanced whole genome sequencing to efficiently identify major genetic variations from a single sample.

This capability not only accelerates the diagnostic process but also enhances treatment strategies, offering substantial improvements in patient outcomes and quality of life. Variantyx reflects values of professionalism, transparency, and diversity, making it a standout entity in its industry.

The company's strategic vision and innovation geared towards rapidly ending the diagnostic odyssey has resonated with investors such as Pitango Venture Capital, Robert Bosch Venture Capital, New Era Capital Partners, and Peregrine Ventures. They collectively contributed to a substantial $36.00M Series D investment round on April 26, 2024, showcasing strong confidence in Variantyx's growth potential and pivotal role in advancing genomic medicine.

Business keywords: Precision Medicine, Genomic Testing, Diagnostic Solutions, Rare Genetic Disorders, Reproductive Genetics, Oncology Treatment Optimization, Whole Genome Sequencing, Genomic Unity®, Genomic Diagnostics, Structural Variants, Mitochondrial Variants, Short Tandem Repeat Expansions, NGS Data Analysis, Clinical Reporting, Cancer Predisposition

Services & Products

Whole Genome Analysis
Exome Plus Analysis
Comprehensive Mitochondrial Disorders Analysis
Hereditary Cancer Analysis
Neurology Analyses
Rapid Genome Sequencing

Target Customers

Healthcare Providers Patients with Rare Genetic Disorders Expectant Parents Individuals with Hereditary Cancer Risks Pediatric Patients

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Series D $36.00M 4
Pitango Venture Capital Robert Bosch Venture Capital New Era Capital Partners
Pitango Venture Capital, Robert Bosch Venture Capital +2
26 Apr 2024
Venture Round Undisclosed 5
20/20 HealthCare Partners Pitango Venture Capital Robert Bosch Venture Capital
20/20 HealthCare Partners, Pitango Venture Capital +3
18 Oct 2023
Debt Financing $20.00M 1
Kreos Capital
Kreos Capital
18 Oct 2022
Series C $41.50M 5
20/20 HealthCare Partners Pitango Venture Capital Robert Bosch Venture Capital
20/20 HealthCare Partners, Pitango Venture Capital +3
14 Feb 2022
Series C $6.00M 1
Robert Bosch Venture Capital
Robert Bosch Venture Capital
15 Nov 2021
Series C $20.00M 5
20/20 HealthCare Partners Pitango Venture Capital IBM Ventures
20/20 HealthCare Partners, Pitango Venture Capital +3
15 Mar 2021
Series B $10.00M 2
Pitango Venture Capital New Era Capital Partners
Pitango Venture Capital, New Era Capital Partners
05 Jun 2019
Series A $3.00M -
07 Dec 2017
Seed Round Undisclosed 1
Co- Founders
28 Jul 2014

Variantyx Alternatives & Competitors

View All Alternatives
Variantyx vs
Ashion Analytics
Ashion Analytics United States

We are an Exact Sciences sequencing-based Clinical laboratory. We tap into the power of the human ge...

3 employees
Biotechnology, Health Care
Compare Variantyx vs Ashion Analytics
Variantyx vs
MEDGENOME
MEDGENOME India

Leader in Genetic Testing Services, Genomics Research and Drug Discovery Solutions

Series D
1011 employees
Biotechnology, Health Care
Compare Variantyx vs MEDGENOME
Variantyx vs
Genoks Genetik Hastalıklar Değerlendirme Merkezi
Genoks Genetik Hastalıklar Değerlendirme Merkezi Turkey

Genlerinize Işık Tutuyoruz!

71 employees
Biotechnology, Life Sciences
Also compare with: Variantyx vs Veritas Intercontinental Veritas Intercontinental View all alternatives

FAQ About Variantyx

Variantyx is a technology-driven precision medicine company providing state-of-the-art genomic testing.
Variantyx was founded in 2014.
Variantyx is headquartered in Framingham, United States.
Variantyx operates in Biotechnology, Health Care and Life Sciences. Its work centres on Precision Medicine, Genomic Testing, Diagnostic Solutions and Rare Genetic Disorders. Its customers include Healthcare Providers, Patients with Rare Genetic Disorders and Expectant Parents.
Variantyx has a B2B, B2C and B2D business model. Its revenue comes from Service Fee, Transaction Fee and Usage Based.
Variantyx has approximately 221 employees.
Variantyx has completed 9 funding rounds, raising a total of $136.50M. The latest funding stage is Series D.
Variantyx offers: Whole Genome Analysis, Exome Plus Analysis, Comprehensive Mitochondrial Disorders Analysis, Hereditary Cancer Analysis, Neurology Analyses, Rapid Genome Sequencing.
Top alternatives and competitors to Variantyx include Ashion Analytics, MEDGENOME, Genoks Genetik Hastalıklar Değerlendirme Merkezi, Veritas Intercontinental, CENTOGENE. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Variantyx and Ashion Analytics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Variantyx, https://bouncewatch.com/company/variantyx, updated 14 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes